Drug Discovery

Automation concept
#Automation #Drug discovery #Lab automation #Laboratory

Busting common myths about lab automation 

Ernesto Staroswiecki, Senior Manager, R&D, at Beckman Coulter Life Sciences takes readers through common lab automation myths.  Many clinical and research laboratories today are having to do more with less: faced with ongoing staffing shortages, increased workloads, and budgetary constraints, many laboratory managers are feeling the stress, which… Read More

#Exclusive Content

Quantum drug discovery
#Artificial intelligence (AI) #Drug design #Drug discovery #Enzymes #Funding #Kuano #Quantum computing

£1.8 million raised to accelerate quantum drug discovery 

Kuano, a drug discovery company combining quantum mechanics with AI to design the next generation of medicines, has raised £1.8M in seed funding, which will facilitate further validation of Kuano’s quantum simulation platform for the design of more effective drug candidates targeting enzymes, as well as continued company growth… Read More

#Business & Investment #News

Future lab, AI and digital data
#Artificial intelligence (AI) #Benchling #Drug discovery #Lab automation #Proscia #Webinar

Webinar: Key benefits and latest innovations in AI and lab automation

Hosted by DDW and co-sponsored by Benchling and Proscia, “AI and Lab Automation: What are the key benefits and latest innovations?” will be free to attend on 10 October at 7AM PDT / 10AM EST / 3PM BST / 4PM CET. Join this free webinar to learn… Read More

#News

#Collaboration #Drug development #Drug discovery #Horizon Europe #Mergers and acquisitions #Partnership

New: DDW Highlights 11 September 2023

The latest episode of the DDW Highlights podcast is now available to listen to below. DDW’s Megan Thomas narrates five key stories of the week to keep DDW subscribers up-to-date on the latest industry updates.  This week we have seen the vital importance of collaboration to the… Read More

#News

AI brain
#AI / data analytics / healthtech / informatics #Artificial intelligence (AI) #Drug discovery #Pharmaceutical industry

Pharma must embrace an AI future says new report

Artificial intelligence (AI) technology has the potential to revolutionise drug discovery and pharma companies need to make plans for a future in which AI is frequently utilised in research, says ResearchAndMarkets.com. However, the change AI will bring about in drug discovery will take some time, according… Read More

#News #Trends & Analysis

#Collaboration #Drug development #Drug discovery #Horizon Europe #Mergers and acquisitions #Partnership

This week in drug discovery (4-8 September)  

News round-up for 4-8 September by DDW Digital Content Editor Diana Spencer. This week we have seen the vital importance of collaboration to the successful development and discovery of novel therapeutics, exemplified by the new deal agreed by the UK and EU to admit the UK… Read More

#News

#Cell and protein analysis #Drug development #Drug discovery #Mass spectrometry / NMR #Regulatory

Podcast: Mass spectrometry advancing drug discovery

This is the latest episode of the free DDW narrated podcast, “How is mass spectrometry advancing drug discovery?”, which covers two articles written for Volume 23, Issue 3 – Summer 2022 of DDW. They are called “Native mass spectrometry: Drug discovery’s new kid on the… Read More

#News

Business financing
#Apollo Therapeutics #Drug discovery #Funding

Apollo Therapeutics closes $226.5 million Series C financing 

Apollo Therapeutics, a biopharmaceutical company focused on translating fundamental medical research into medicines through a hub-and-spoke approach, has closed $226.5 million in a Series C financing, led by lead investor Patient Square Capital.  Financing significantly adds to the $195 million previously raised by the company, and to… Read More

#Business & Investment #News

ulcerative colitis
#AI #BenevolentAI #Drug discovery #Ulcerative colitis (UC)

First patients dosed with an AI-derived target for ulcerative colitis 

BenevolentAI has dosed the first patients in Phase I first-in-human studies of its oral phosphodiesterase 10 (PDE10) inhibitor, BEN-8744, intended for the treatment of ulcerative colitis (UC). The topline data readout from this study is expected in the first quarter of 2024.  UC is a chronic disease… Read More

#News

eBook
#Biosensors #Drug discovery #eBook #Interaction analysis #Molecular research #Pharmokinetics

Binding kinetics in hours instead of days – download the eBook

A new eBook is now available from Malvern Panalytical: ‘Faster, more accurate and deeper insight: How to make the switch to label-free interaction analysis.’ Label-free interaction analysis takes discovery to a new level. It removes inaccuracies and inefficiencies, but it also uncovers a new layer of insight… Read More

#News

#Biosensors #Drug discovery #Interaction analysis #Molecular research #Pharmokinetics

Binding kinetics in hours instead of days with label-free interaction analysis

Label-free interaction analysis takes discovery to a new level. It removes inaccuracies and inefficiencies, but it also uncovers a new layer of insight into the kinetic activity and binding specificity of a greater range of analytes. GCI technology brings you closer to your analytes, allowing you to see interactions in… Read More

#Resources

New appointments
#Appointment #Drug discovery #New appointment

Drug discovery’s latest top-level appointments

It’s not unusual for such a dynamic industry to have regular shake-ups in senior leadership, especially as innovative new technologies create brand new roles. The last couple of months have seen a number of high-profile job moves in drug discovery. Dr Robert Kirby, COO and Dr Edward Stevens,… Read More

#Business & Investment #News

#BioInnovation Institute #Drug discovery #Funding #Investment #Start-ups

Three therapeutics start-ups join acceleration programme

The BioInnovation Institute (BII) has welcomed three new drug discovery start-ups into its Venture Lab acceleration programme as part of its latest cohort of eight companies. The 12-month Venture Lab programme is designed to support start-up companies with business acceleration, scientific and team development, and provides… Read More

#News #Start-up Zone

Danaher Corporation
#Abcam #Danaher Corporation #Drug discovery #Mergers and acquisitions

Danaher to acquire Abcam

The two companies have entered an agreement in which Danaher Corporation will acquire Abcam for $24 per share in cash. The transaction has been unanimously approved and recommended by the Abcam Board of Directors and unanimously approved by the Danaher Board of Directors. Founded… Read More

#Business & Investment #News

#ADME / Tox #Drug development #Drug discovery #Regulatory #Webinar

Register now: Why are ADME and DDI investigations important?

Join DDW for this exclusive free event, Are in vitro metabolism and drug-drug interaction studies critical for an investigational new drug application? which is supported by BioIVT. Expert Dr Andrew G Taylor, PhD, ADME Technical Sales Specialist, BioIVT, will present this event which will take place… Read More

Webinar date:
Supported by BioIVT
#News